This analysis covers Potato's go-to-market for life science R&D teams, focusing on wet-lab biologists, computational biologists, and automation engineers in pharma, biotech, and academia.
Segments were chosen based on pain intensity (manual protocol writing, literature search, data analysis), data availability (NIH RePORTER, ClinicalTrials.gov, PubMed, SEC filings), and message specificity (e.g., referencing a specific grant or pipeline program).
Wet-lab biologists spend 30-40% of their time on literature search, protocol writing, and data analysis rather than running experiments. At an average loaded cost of $150,000/year per researcher, a 50-person R&D team loses $2.25-3M annually to these tasks. NIH and FDA grant reviewers increasingly expect reproducible, well-documented protocols — delays in protocol generation can push back grant submissions and regulatory filings.
Each month of delay in preclinical development costs a biotech $1-2M in lost time-to-market and investor confidence. A 6-month delay in IND filing can reduce peak revenue by 10-15% (per Tufts CSDD estimates). For a drug with $500M peak sales, that's $50-75M in lost value.
| # | Segment | TAM | Pain | Conversion | Score |
|---|---|---|---|---|---|
| 1 | Mid-Size Biotech R&D Teams NAICS 541714 · USA · ~800 companies | ~800 | 0.90 | 15% | 88 / 100 |
| 2 | Large Pharma R&D Units NAICS 325412 · USA/UK/EU · ~200 companies | ~200 | 0.85 | 12% | 82 / 100 |
| 3 | Academic Medical Centers & Core Labs NAICS 611310 · USA/UK/EU · ~500 institutions | ~500 | 0.80 | 10% | 78 / 100 |
| 4 | CROs with R&D Services NAICS 541380 · USA/UK/EU · ~300 companies | ~300 | 0.75 | 8% | 74 / 100 |
| 5 | AI-First Biotech Startups NAICS 541714 · USA/UK/EU · ~150 companies | ~150 | 0.70 | 6% | 71 / 100 |
The pain. For a mid-size biotech with 50 researchers, manual protocol creation and literature review costs $1.2M/year in lost researcher time and delays IND filings by 3-6 months. Most R&D directors don't realize this is a structural data problem, not a staffing issue.
How to identify them. Use the NIH RePORTER database to filter for biotech companies with 30-100 employees and active NIH grants in drug discovery. Cross-reference with Crunchbase to confirm R&D headcount and funding stage (Series B to D).
Why they convert. These teams are under pressure to accelerate IND timelines from investors and partners, making them highly receptive to automation tools. A 20% reduction in protocol creation time directly translates to faster regulatory submissions and reduced burn rate.
The pain. In large pharma, hundreds of researchers manually compile protocols and literature reviews across therapeutic areas, leading to $5M+ annual productivity loss per R&D unit. The fragmentation of data across teams creates duplication and inconsistent standards that delay Phase 1 starts.
How to identify them. Query the EMA Clinical Trials Register and ClinicalTrials.gov for companies with over 500 active trials and R&D sites in the US, UK, and EU. Filter by companies with dedicated digital transformation officers in their R&D leadership team via LinkedIn Sales Navigator.
Why they convert. Large pharma are under regulatory pressure to digitize R&D workflows (e.g., FDA's push for digital data standards) and have dedicated budgets for AI/automation tools. A proven ROI case from a mid-size biotech peer creates a compelling internal justification for procurement.
The pain. Academic core labs supporting translational research spend 30% of their time on manual protocol authoring and literature synthesis, diverting effort from grant-funded experiments. This slows down multi-institutional collaborations and delays publication of high-impact findings.
How to identify them. Use the NIH RePORTER to find academic institutions with $10M+ in annual R&D funding and active core lab facilities listed on their websites. Cross-reference with the UKRI Gateway to Research for UK institutions and the European Research Council database for EU-funded projects.
Why they convert. These labs are constantly training new graduate students and postdocs, making standardized protocol creation a critical efficiency gain. They are early adopters of open-source tools and willing to pilot new software if it improves reproducibility and reduces onboarding time.
The pain. Contract Research Organizations (CROs) that offer preclinical and clinical R&D services must produce custom protocols and literature reviews for each client, costing $500K+ annually in manual effort per mid-size CRO. This erodes margins on fixed-price contracts and limits scalability.
How to identify them. Search the FDA's Bioresearch Monitoring Information System for CROs with active clinical investigator sites. Filter by those listed on the UK Medicines and Healthcare products Regulatory Agency (MHRA) GCP compliance database and with 100-500 employees on LinkedIn.
Why they convert. CROs face intense competition on price and turnaround time, making any tool that reduces labor costs a direct competitive advantage. They are accustomed to paying for software that improves operational efficiency and can quickly demonstrate ROI to their clients.
The pain. AI-first biotechs with small teams (10-30 researchers) rely heavily on automated data pipelines but still manually create protocols and literature reviews, creating a bottleneck in their otherwise efficient R&D process. This inconsistency slows down their rapid iteration cycles and model validation.
How to identify them. Use the NIH RePORTER to find startups with SBIR/STTR grants in AI or machine learning applied to drug discovery. Cross-reference with the UK's Innovate UK funding database and the EU's Horizon Europe project portal for AI in health startups.
Why they convert. These startups are culturally aligned with automation and are actively seeking tools to eliminate manual steps in their workflows. They have smaller budgets but are willing to pay for high-impact tools that integrate with their existing AI platforms, and they often become vocal advocates.
| Database | Country | Reliability | What it reveals | Used in |
|---|---|---|---|---|
| NIH RePORTER | USA | HIGH | Grant title, award number, organization name, PI name, award amount, project start/end dates, and project abstract for SBIR/STTR awards. | Play 1 |
| Horizon Europe Project Portal | EU | HIGH | Project title, grant agreement number, SME participant name, coordinator, project start/end dates, total budget, and project summary. | Play 1 |
| LinkedIn Sales Navigator | Global | MEDIUM | Company headcount, employee job titles, tech stack keywords, and recent posts about IND filings or funding. | Play 1 |
| Crunchbase | Global | MEDIUM | Company funding rounds, total funding amount, investors, and recent news about IND filings or clinical trials. | Play 1 |
| ClinicalTrials.gov | USA | HIGH | Clinical trial status, sponsor name, intervention, start/completion dates, and FDA IND number (if applicable). | Play 1 |
| EMA Clinical Trials Register | EU | HIGH | Clinical trial application number, sponsor, protocol title, and trial status in the EU. | Play 1 |
| FDA Bioresearch Monitoring Information System | USA | HIGH | FDA inspection history, clinical investigator names, and compliance actions related to IND submissions. | Play 1 |
| MHRA GCP Compliance Database | UK | HIGH | UK clinical trial authorizations, GCP inspection outcomes, and sponsor compliance status. | Play 1 |
| UKRI Gateway to Research | UK | HIGH | UKRI-funded project titles, lead organization, PI name, project start/end dates, and award amount. | Play 1 |
| Innovate UK Funding Database | UK | HIGH | Innovate UK grant titles, SME applicant names, project summaries, and funding amounts. | Play 1 |
| European Research Council Database | EU | HIGH | ERC grant titles, principal investigator names, host institution, and project duration. | Play 1 |
| NIH SBIR/STTR Awards | USA | HIGH | List of all active SBIR/STTR awards by company, including award number, PI, and project dates. | Play 1 |